Genentech Provides Update On Avastin For Metastatic Breast Cancer Following Reviews I

tD33NAt

Active member
Joined
Mar 24, 2008
Messages
12,519
Reaction score
0
Points
36
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities: "the benefits of this combination outweigh its risks and that this combination remains a valuable treatment option for patients suffering from metastatic breast cancer...


JCElM-HhlFc


More...
 
Back
Top